TR201005241A1 - Kontrollü salım sağlayan pregabalin solüsyon formülasyonu. - Google Patents

Kontrollü salım sağlayan pregabalin solüsyon formülasyonu.

Info

Publication number
TR201005241A1
TR201005241A1 TR2010/05241A TR201005241A TR201005241A1 TR 201005241 A1 TR201005241 A1 TR 201005241A1 TR 2010/05241 A TR2010/05241 A TR 2010/05241A TR 201005241 A TR201005241 A TR 201005241A TR 201005241 A1 TR201005241 A1 TR 201005241A1
Authority
TR
Turkey
Prior art keywords
controlled release
solution formulation
pregabalin
pregabalin solution
formulation
Prior art date
Application number
TR2010/05241A
Other languages
English (en)
Inventor
�M�T ��Fter Musa
T�Rkyilmaz Al�
Pehl�Van Akalin Nur
Original Assignee
Sanovel �La� San. Ve T�C. A.�.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanovel �La� San. Ve T�C. A.�. filed Critical Sanovel �La� San. Ve T�C. A.�.
Priority to TR2010/05241A priority Critical patent/TR201005241A1/tr
Priority to EP11167335A priority patent/EP2389935A1/en
Priority to US13/115,725 priority patent/US20110294887A1/en
Publication of TR201005241A1 publication Critical patent/TR201005241A1/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Buluş midede jelleşen ve kontrollü salım sağlayan oral solüsyon formülasyonu olup, pregabalin veya pregabalinin farmasötik olarak kabul edilebilir bir tuzu ile jelleştirici ajan içermektedir.
TR2010/05241A 2010-05-25 2010-06-29 Kontrollü salım sağlayan pregabalin solüsyon formülasyonu. TR201005241A1 (tr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
TR2010/05241A TR201005241A1 (tr) 2010-05-25 2010-06-29 Kontrollü salım sağlayan pregabalin solüsyon formülasyonu.
EP11167335A EP2389935A1 (en) 2010-05-25 2011-05-24 Controlled-Release oral Solution Formulations of Pregabalin
US13/115,725 US20110294887A1 (en) 2010-05-25 2011-05-25 Controlled-release solution formulations of pregabalin

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
TR201004139 2010-05-25
TR201005145 2010-06-25
TR2010/05241A TR201005241A1 (tr) 2010-05-25 2010-06-29 Kontrollü salım sağlayan pregabalin solüsyon formülasyonu.

Publications (1)

Publication Number Publication Date
TR201005241A1 true TR201005241A1 (tr) 2012-01-23

Family

ID=44225825

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2010/05241A TR201005241A1 (tr) 2010-05-25 2010-06-29 Kontrollü salım sağlayan pregabalin solüsyon formülasyonu.

Country Status (3)

Country Link
US (1) US20110294887A1 (tr)
EP (1) EP2389935A1 (tr)
TR (1) TR201005241A1 (tr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3062782A1 (en) * 2013-10-30 2016-09-07 Pharnext Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level
CN113616591B (zh) * 2021-09-03 2023-05-23 贝克诺顿(浙江)制药有限公司 一种普瑞巴林口服溶液及制备方法
CN120585747B (zh) * 2025-06-17 2026-02-10 北京诺和动保科技有限公司 普瑞巴林内服溶液及其制备方法和应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007052125A2 (en) * 2005-11-02 2007-05-10 Pfizer Products Inc. Solid oral pharmaceutical compositions for once daily dosing containing pregabalin, a matrix forming agent and a swelling agent
DE102007019071A1 (de) * 2007-04-23 2008-10-30 Ratiopharm Gmbh Stabilisierte pharmazeutische Zusammensetzung enthaltend Pregabalin
WO2009066325A1 (en) * 2007-11-23 2009-05-28 Lupin Limited Controlled release pharmaceutical compositions of pregabalin
WO2010143052A1 (en) * 2009-06-12 2010-12-16 Micro Labs Limited Novel pharmaceutical compositions containing pregabalin

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5102666A (en) * 1990-09-11 1992-04-07 Oramed, Inc. Calcium polycarbophil controlled release composition and method
IL139298A0 (en) 1998-05-15 2001-11-25 Warner Lambert Co Stabilized pharmaceutical preparations of gamma-aminobutyric acid derivatives and process for preparing the same
GB9910212D0 (en) * 1999-05-05 1999-06-30 Reckitt & Colmann Prod Ltd Improvements in or relating to organic compositions
BR0209973A (pt) * 2001-05-25 2004-04-06 Warner Lambert Co Composição farmacêutica lìquida
US20040010034A1 (en) * 2002-07-10 2004-01-15 Ciociola Arthur A. Gastrointestinal compositions
EP1543831A1 (en) * 2003-12-18 2005-06-22 Pfizer GmbH Arzneimittelwerk Gödecke Pregabalin composition
US7417165B2 (en) * 2005-04-06 2008-08-26 Teva Pharmaceutical Industries Ltd. Crystalline forms of pregabalin
WO2008008120A1 (en) 2006-07-14 2008-01-17 Fmc Corporation Solid form
WO2008140459A1 (en) 2007-05-16 2008-11-20 Fmc Corporation Solid form
WO2008140460A1 (en) 2007-05-16 2008-11-20 Fmc Corporation Solid form
WO2009080365A1 (en) * 2007-12-21 2009-07-02 Synthon B.V. Pregabalin salts
US8329750B2 (en) * 2008-02-11 2012-12-11 Depomed, Inc. Methods for treating vasomotor symptoms using GABA analogs in a gastric retentive dosage form

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007052125A2 (en) * 2005-11-02 2007-05-10 Pfizer Products Inc. Solid oral pharmaceutical compositions for once daily dosing containing pregabalin, a matrix forming agent and a swelling agent
DE102007019071A1 (de) * 2007-04-23 2008-10-30 Ratiopharm Gmbh Stabilisierte pharmazeutische Zusammensetzung enthaltend Pregabalin
WO2009066325A1 (en) * 2007-11-23 2009-05-28 Lupin Limited Controlled release pharmaceutical compositions of pregabalin
WO2010143052A1 (en) * 2009-06-12 2010-12-16 Micro Labs Limited Novel pharmaceutical compositions containing pregabalin

Also Published As

Publication number Publication date
US20110294887A1 (en) 2011-12-01
EP2389935A1 (en) 2011-11-30

Similar Documents

Publication Publication Date Title
MX2020010607A (es) Compuestos y metodos para inhibir el transporte de fosfato.
UA111717C2 (uk) Склад для перорального введення і ліпофільні солі метилналтрексону
HUE037088T2 (hu) Amiszulpirid ópiát-okozta hányinger és hányás terápiájában való alkalmazásra
UA109037C2 (uk) Триазолопіридини
PH12013500223A1 (en) Oral care product and methods of use and manufacture thereof
EA201291211A1 (ru) Фармацевтические композиции, содержащие гидроморфон и налоксон
MX2011011109A (es) Formulaciones orales de bendamustina.
TR201107481A1 (tr) Vildagliptinin efervesan formülasyonları.
EA201270728A1 (ru) Пуриновые соединения
TR201001417A1 (tr) Geliştirilmiş çözünme hızına sahip sefdinir formülasyonu
TR201001862A1 (tr) Kontrollü salım gerçekleştiren pramipeksol formülasyonları.
PH12014501304A1 (en) Oral care compositions
TR200906506A2 (tr) Telmisartan içeren katı dozaj formları.
EA201201329A1 (ru) Новая композиция для лечения эссенциальной тромбоцитемии
TR201007926A1 (tr) Prasugrel tablet formülasyonları.
TR201101809A1 (tr) Vildagliptin ve glimepirid kombinasyonları.
EA201500446A1 (ru) Фармацевтическая композиция для снижения уровня n-оксида триметиламина
EA201590732A1 (ru) Диспергируемая таблетка
TR201009399A2 (tr) Hızlı çözünen efervesan rosuvastatin formülasyonları.
TR201102857A2 (tr) Telmisartan ve diüretik kombinasyonunun farmasötik formülasyonları.
TR201100151A2 (tr) İbandronate formülasyonu.
TR200906322A2 (tr) Çözünürlük ve stabilite özellikleri geliştirilmiş granüller.
EA201270727A1 (ru) Пуриновые соединения
TR201107563A1 (tr) Vildagliptin ve gliklazid kombinasyon kompozisyonu.
TR201009395A2 (tr) Tadı iyileştirilmiş efervesan formülasyonlar.